A benzylidene mannopyranoside derivative with antitumor activity in the spontaneous mammary tumor system.
Methyl 2,3,4,6-di-O-benzylidene alpha-D-mannopyranoside (MeDBMP) was synthesized to evaluate its potential as a cytotoxic benzaldehyde liberating agent. MeDBMP was found to cause significant reductions in the sizes of spontaneous mouse mammary carcinomas and to produce long term alterations in their growth characteristics. It was nontoxic at all doses examined and possessed no mutagenic properties in the Ames Salmonella/mammalian-microsome test.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001547:Benzaldehydes / Q000494:pharmacology; D005260:Female; D006027:Glycosides / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D008362:Mannosides / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009153:Mutagens
D000970:Antineoplastic Agents; D001547:Benzaldehydes; D006027:Glycosides; D008362:Mannosides; D009153:Mutagens